trending Market Intelligence /marketintelligence/en/news-insights/trending/mgJD1tpA9AaEwHbQYGLuEA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Innovate using funds from $9.7M offering for study of autoimmune disorder drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Innovate using funds from $9.7M offering for study of autoimmune disorder drug

Innovate Biopharmaceuticals Inc. closed an equity financing with $9.7 million in gross proceeds.

The Raleigh, N.C.-based company planned to sell up to 4,291,845 common shares at $2.33 each and 4,291,845 12-month term warrants exercisable at $4 per share to SDS Capital Partners II LLC and certain other investors.

The company also previously said it would sell up to 2,575,107 five-year term warrants, which will be exercisable six months after issuance.

Innovate said it plans to use about $9.6 million in net proceeds to launch its first phase 3 trial for INN-202 as a treatment for celiac disease as well as for working capital and general corporate purposes. Celiac disease is a serious autoimmune disorder that can occur in genetically predisposed people where gluten intake leads to damage in the small intestine.

Innovate Biopharmaceuticals develops therapies for autoimmune and inflammatory diseases.